A Phase 3 registration trial of MGL-3196 for familial hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2018
At a glance
- Drugs MGL-3196 (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Madrigal Pharmaceuticals
- 06 Nov 2018 According to a Madrigal Pharmaceuticals media release, this trial is expected to begin in 2019.
- 18 May 2017 New trial record
- 11 May 2017 According to a Madrigal Pharmaceuticals media release, this trial is expected to begin in 2018.